Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate
The objective of present work was to develop taste masked orodispersible tablets of mirabegron. Mirabegron is beta 3 adrenoceptor agonist used to treat overactive bladder. Overactive bladder (OAB) is defined as a symptom syndrome showing feeling of urgency to urinate, typically accompanied by freque...
Gespeichert in:
Veröffentlicht in: | Research journal of pharmacy and technology 2021-09, Vol.14 (9), p.4736-4742 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4742 |
---|---|
container_issue | 9 |
container_start_page | 4736 |
container_title | Research journal of pharmacy and technology |
container_volume | 14 |
creator | Malode, Sarika S. Wagh, Milind P. |
description | The objective of present work was to develop taste masked orodispersible tablets of mirabegron. Mirabegron is beta 3 adrenoceptor agonist used to treat overactive bladder. Overactive bladder (OAB) is defined as a symptom syndrome showing feeling of urgency to urinate, typically accompanied by frequent daytime and nocturnal urination, in the absence of proven infection or other obvious pathology. Over active bladders are generally common in geriatrics. Moreover, this drug has a very strong bitter taste. Frequent dosing requires frequent water intake, which further aggregates the condition of over active bladder and bitter taste of drug affects patient compliance. Hence a need arises to mask the bitter taste for development of an ODT which does not require consuming water with every dosage. In this work, the bitter taste of mirabegron was masked by forming a complex with an ion exchange resin tulsion 344. The drug resin complexation process was optimized for resin activation, drug: resin ratio, soaking time and stirring time. In –vitro release studies revealed complete drug elution from the complex within 10 minutes in pH 1.2 buffer. The taste-masked complex was then formulated into palatable orodispersible tablets using a direct compression approach by use of superdisintegrants to achieve a rapid disintegration. The tablets were evaluated for weight variation, hardness, friability, drug content, wetting time, In- vivo disintegration time and in-vitro dissolution time. |
doi_str_mv | 10.52711/0974-360X.2021.00824 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2671370026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2671370026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c196t-1a5798aa099ab2535fa4e5412f8ed4707cc931a4062936abed9c89eb99e949433</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMoOOZ-ghDwujOfbXMpY1NhYyATvIunbToyu2YmqeC_N9tk5-J8vJxzXngQuqdkKllB6SNRhch4Tj6mjDA6JaRk4gqNLvL1paflLZqEsCMp8lIyUY7Q58L5_dBBtK7H0Dd4_gPdcB5di9feNTYcjA-26gzeQMox4JnrI9je9tskhWjwCsKXafDKeqjM1qfjNxNsD9HcoZsWumAm_3WM3hfzzewlW66fX2dPy6ymKo8ZBVmoEoAoBRWTXLYgjBSUtaVpREGKulacgiA5UzxPJo2qS2UqpYwSSnA-Rg_nvwfvvgcTot65wffJUrO8oLwghOVpS563au9C8KbVB2_34H81JfrEUx9h6SM4feSpTzz5H11xaM4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2671370026</pqid></control><display><type>article</type><title>Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Malode, Sarika S. ; Wagh, Milind P.</creator><creatorcontrib>Malode, Sarika S. ; Wagh, Milind P.</creatorcontrib><description>The objective of present work was to develop taste masked orodispersible tablets of mirabegron. Mirabegron is beta 3 adrenoceptor agonist used to treat overactive bladder. Overactive bladder (OAB) is defined as a symptom syndrome showing feeling of urgency to urinate, typically accompanied by frequent daytime and nocturnal urination, in the absence of proven infection or other obvious pathology. Over active bladders are generally common in geriatrics. Moreover, this drug has a very strong bitter taste. Frequent dosing requires frequent water intake, which further aggregates the condition of over active bladder and bitter taste of drug affects patient compliance. Hence a need arises to mask the bitter taste for development of an ODT which does not require consuming water with every dosage. In this work, the bitter taste of mirabegron was masked by forming a complex with an ion exchange resin tulsion 344. The drug resin complexation process was optimized for resin activation, drug: resin ratio, soaking time and stirring time. In –vitro release studies revealed complete drug elution from the complex within 10 minutes in pH 1.2 buffer. The taste-masked complex was then formulated into palatable orodispersible tablets using a direct compression approach by use of superdisintegrants to achieve a rapid disintegration. The tablets were evaluated for weight variation, hardness, friability, drug content, wetting time, In- vivo disintegration time and in-vitro dissolution time.</description><identifier>ISSN: 0974-3618</identifier><identifier>EISSN: 0974-360X</identifier><identifier>EISSN: 0974-306X</identifier><identifier>DOI: 10.52711/0974-360X.2021.00824</identifier><language>eng</language><publisher>Raipur: A&V Publications</publisher><subject>Bladder ; Drug delivery systems ; Drug dosages ; Patient compliance ; Resins ; Spectrum analysis</subject><ispartof>Research journal of pharmacy and technology, 2021-09, Vol.14 (9), p.4736-4742</ispartof><rights>Copyright A&V Publications Sep 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c196t-1a5798aa099ab2535fa4e5412f8ed4707cc931a4062936abed9c89eb99e949433</citedby><cites>FETCH-LOGICAL-c196t-1a5798aa099ab2535fa4e5412f8ed4707cc931a4062936abed9c89eb99e949433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Malode, Sarika S.</creatorcontrib><creatorcontrib>Wagh, Milind P.</creatorcontrib><title>Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate</title><title>Research journal of pharmacy and technology</title><description>The objective of present work was to develop taste masked orodispersible tablets of mirabegron. Mirabegron is beta 3 adrenoceptor agonist used to treat overactive bladder. Overactive bladder (OAB) is defined as a symptom syndrome showing feeling of urgency to urinate, typically accompanied by frequent daytime and nocturnal urination, in the absence of proven infection or other obvious pathology. Over active bladders are generally common in geriatrics. Moreover, this drug has a very strong bitter taste. Frequent dosing requires frequent water intake, which further aggregates the condition of over active bladder and bitter taste of drug affects patient compliance. Hence a need arises to mask the bitter taste for development of an ODT which does not require consuming water with every dosage. In this work, the bitter taste of mirabegron was masked by forming a complex with an ion exchange resin tulsion 344. The drug resin complexation process was optimized for resin activation, drug: resin ratio, soaking time and stirring time. In –vitro release studies revealed complete drug elution from the complex within 10 minutes in pH 1.2 buffer. The taste-masked complex was then formulated into palatable orodispersible tablets using a direct compression approach by use of superdisintegrants to achieve a rapid disintegration. The tablets were evaluated for weight variation, hardness, friability, drug content, wetting time, In- vivo disintegration time and in-vitro dissolution time.</description><subject>Bladder</subject><subject>Drug delivery systems</subject><subject>Drug dosages</subject><subject>Patient compliance</subject><subject>Resins</subject><subject>Spectrum analysis</subject><issn>0974-3618</issn><issn>0974-360X</issn><issn>0974-306X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kF1LwzAUhoMoOOZ-ghDwujOfbXMpY1NhYyATvIunbToyu2YmqeC_N9tk5-J8vJxzXngQuqdkKllB6SNRhch4Tj6mjDA6JaRk4gqNLvL1paflLZqEsCMp8lIyUY7Q58L5_dBBtK7H0Dd4_gPdcB5di9feNTYcjA-26gzeQMox4JnrI9je9tskhWjwCsKXafDKeqjM1qfjNxNsD9HcoZsWumAm_3WM3hfzzewlW66fX2dPy6ymKo8ZBVmoEoAoBRWTXLYgjBSUtaVpREGKulacgiA5UzxPJo2qS2UqpYwSSnA-Rg_nvwfvvgcTot65wffJUrO8oLwghOVpS563au9C8KbVB2_34H81JfrEUx9h6SM4feSpTzz5H11xaM4</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Malode, Sarika S.</creator><creator>Wagh, Milind P.</creator><general>A&V Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04S</scope><scope>04W</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20210901</creationdate><title>Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate</title><author>Malode, Sarika S. ; Wagh, Milind P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c196t-1a5798aa099ab2535fa4e5412f8ed4707cc931a4062936abed9c89eb99e949433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bladder</topic><topic>Drug delivery systems</topic><topic>Drug dosages</topic><topic>Patient compliance</topic><topic>Resins</topic><topic>Spectrum analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Malode, Sarika S.</creatorcontrib><creatorcontrib>Wagh, Milind P.</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Business</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Research journal of pharmacy and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malode, Sarika S.</au><au>Wagh, Milind P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate</atitle><jtitle>Research journal of pharmacy and technology</jtitle><date>2021-09-01</date><risdate>2021</risdate><volume>14</volume><issue>9</issue><spage>4736</spage><epage>4742</epage><pages>4736-4742</pages><issn>0974-3618</issn><eissn>0974-360X</eissn><eissn>0974-306X</eissn><abstract>The objective of present work was to develop taste masked orodispersible tablets of mirabegron. Mirabegron is beta 3 adrenoceptor agonist used to treat overactive bladder. Overactive bladder (OAB) is defined as a symptom syndrome showing feeling of urgency to urinate, typically accompanied by frequent daytime and nocturnal urination, in the absence of proven infection or other obvious pathology. Over active bladders are generally common in geriatrics. Moreover, this drug has a very strong bitter taste. Frequent dosing requires frequent water intake, which further aggregates the condition of over active bladder and bitter taste of drug affects patient compliance. Hence a need arises to mask the bitter taste for development of an ODT which does not require consuming water with every dosage. In this work, the bitter taste of mirabegron was masked by forming a complex with an ion exchange resin tulsion 344. The drug resin complexation process was optimized for resin activation, drug: resin ratio, soaking time and stirring time. In –vitro release studies revealed complete drug elution from the complex within 10 minutes in pH 1.2 buffer. The taste-masked complex was then formulated into palatable orodispersible tablets using a direct compression approach by use of superdisintegrants to achieve a rapid disintegration. The tablets were evaluated for weight variation, hardness, friability, drug content, wetting time, In- vivo disintegration time and in-vitro dissolution time.</abstract><cop>Raipur</cop><pub>A&V Publications</pub><doi>10.52711/0974-360X.2021.00824</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0974-3618 |
ispartof | Research journal of pharmacy and technology, 2021-09, Vol.14 (9), p.4736-4742 |
issn | 0974-3618 0974-360X 0974-306X |
language | eng |
recordid | cdi_proquest_journals_2671370026 |
source | EZB-FREE-00999 freely available EZB journals |
subjects | Bladder Drug delivery systems Drug dosages Patient compliance Resins Spectrum analysis |
title | Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A27%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20and%20Evaluation%20of%20Orodispersible%20Tablets%20Containing%20Taste%20Masked%20Mirabegron%20Resinate&rft.jtitle=Research%20journal%20of%20pharmacy%20and%20technology&rft.au=Malode,%20Sarika%20S.&rft.date=2021-09-01&rft.volume=14&rft.issue=9&rft.spage=4736&rft.epage=4742&rft.pages=4736-4742&rft.issn=0974-3618&rft.eissn=0974-360X&rft_id=info:doi/10.52711/0974-360X.2021.00824&rft_dat=%3Cproquest_cross%3E2671370026%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2671370026&rft_id=info:pmid/&rfr_iscdi=true |